Thrombolytic therapy for right-sided mechanical pulmonic and tricuspid valves: The largest survival analysis to date

Maryam Taherkhani, Seyed Reza Hashemi, Manouchehr Hekmat, Morteza Safi, Adineh Taherkhani, Mohammad R Movahed

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Data regarding thrombolytic treatment of right-sided mechanical valve thrombosis are almost nonexistent, and all current guidelines arise from very small case series. We retrospectively studied the in-hospital and long-term outcome data of a larger series of patients who had received, from September 2005 through June 2012, thrombolytic therapy for right-sided mechanical pulmonary valve or tricuspid valve thrombosis. We identified 16 patients aged 8–67 years who had undergone thrombolytic therapy for definite thrombotic mechanical valve obstruction in the tricuspid or pulmonary valve position (8 in each position). All study patients except one had subtherapeutic international normalized ratios. The 8 patients with pulmonary mechanical valve thrombosis had a 100% response rate to thrombolytic therapy, and their in-hospital survival rate was also 100%. The 8 patients with tricuspid mechanical valve thrombosis had a 75% response rate to thrombolytic therapy, with an in-hospital survival rate of 87.5%. The one-year survival rate for mechanical valve thrombosis treated with thrombolytic therapy (whether pulmonary or tricuspid) was 87.5%. On the basis of our data, we recommend that thrombolytic therapy remain the firstline therapy for right-sided mechanical valve thrombosis in adults or children—including children with complex congenital heart disease and patients with mechanical pulmonary valve thrombosis. Surgery should be reserved for patients in whom this treatment fails.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalTexas Heart Institute Journal
Volume42
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

Tricuspid Valve
Thrombolytic Therapy
Survival Analysis
Thrombosis
Pulmonary Valve
Lung
Survival Rate
International Normalized Ratio
Heart Diseases
Therapeutics
Guidelines

Keywords

  • Alteplase/ therapeutic use
  • Echocardiography
  • Fluoroscopy
  • Heart valve prosthesis
  • Mechanical/ dysfunction/mortality
  • Pulmonary valve
  • Recombinant tissue plasminogen activator/therapeutic use
  • Streptokinase/ therapeutic use
  • Thromboembolism/ drug therapy
  • Thrombolytic therapy
  • Transesophageal
  • Treatment outcome
  • Tricuspid valve

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Thrombolytic therapy for right-sided mechanical pulmonic and tricuspid valves : The largest survival analysis to date. / Taherkhani, Maryam; Hashemi, Seyed Reza; Hekmat, Manouchehr; Safi, Morteza; Taherkhani, Adineh; Movahed, Mohammad R.

In: Texas Heart Institute Journal, Vol. 42, No. 6, 01.12.2015, p. 543-547.

Research output: Contribution to journalArticle

Taherkhani, Maryam ; Hashemi, Seyed Reza ; Hekmat, Manouchehr ; Safi, Morteza ; Taherkhani, Adineh ; Movahed, Mohammad R. / Thrombolytic therapy for right-sided mechanical pulmonic and tricuspid valves : The largest survival analysis to date. In: Texas Heart Institute Journal. 2015 ; Vol. 42, No. 6. pp. 543-547.
@article{469428480ff74139b856ab46e5c1015a,
title = "Thrombolytic therapy for right-sided mechanical pulmonic and tricuspid valves: The largest survival analysis to date",
abstract = "Data regarding thrombolytic treatment of right-sided mechanical valve thrombosis are almost nonexistent, and all current guidelines arise from very small case series. We retrospectively studied the in-hospital and long-term outcome data of a larger series of patients who had received, from September 2005 through June 2012, thrombolytic therapy for right-sided mechanical pulmonary valve or tricuspid valve thrombosis. We identified 16 patients aged 8–67 years who had undergone thrombolytic therapy for definite thrombotic mechanical valve obstruction in the tricuspid or pulmonary valve position (8 in each position). All study patients except one had subtherapeutic international normalized ratios. The 8 patients with pulmonary mechanical valve thrombosis had a 100{\%} response rate to thrombolytic therapy, and their in-hospital survival rate was also 100{\%}. The 8 patients with tricuspid mechanical valve thrombosis had a 75{\%} response rate to thrombolytic therapy, with an in-hospital survival rate of 87.5{\%}. The one-year survival rate for mechanical valve thrombosis treated with thrombolytic therapy (whether pulmonary or tricuspid) was 87.5{\%}. On the basis of our data, we recommend that thrombolytic therapy remain the firstline therapy for right-sided mechanical valve thrombosis in adults or children—including children with complex congenital heart disease and patients with mechanical pulmonary valve thrombosis. Surgery should be reserved for patients in whom this treatment fails.",
keywords = "Alteplase/ therapeutic use, Echocardiography, Fluoroscopy, Heart valve prosthesis, Mechanical/ dysfunction/mortality, Pulmonary valve, Recombinant tissue plasminogen activator/therapeutic use, Streptokinase/ therapeutic use, Thromboembolism/ drug therapy, Thrombolytic therapy, Transesophageal, Treatment outcome, Tricuspid valve",
author = "Maryam Taherkhani and Hashemi, {Seyed Reza} and Manouchehr Hekmat and Morteza Safi and Adineh Taherkhani and Movahed, {Mohammad R}",
year = "2015",
month = "12",
day = "1",
doi = "10.14503/THIJ-14-4659",
language = "English (US)",
volume = "42",
pages = "543--547",
journal = "Texas Heart Institute Journal",
issn = "0730-2347",
publisher = "Texas Heart Institute",
number = "6",

}

TY - JOUR

T1 - Thrombolytic therapy for right-sided mechanical pulmonic and tricuspid valves

T2 - The largest survival analysis to date

AU - Taherkhani, Maryam

AU - Hashemi, Seyed Reza

AU - Hekmat, Manouchehr

AU - Safi, Morteza

AU - Taherkhani, Adineh

AU - Movahed, Mohammad R

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Data regarding thrombolytic treatment of right-sided mechanical valve thrombosis are almost nonexistent, and all current guidelines arise from very small case series. We retrospectively studied the in-hospital and long-term outcome data of a larger series of patients who had received, from September 2005 through June 2012, thrombolytic therapy for right-sided mechanical pulmonary valve or tricuspid valve thrombosis. We identified 16 patients aged 8–67 years who had undergone thrombolytic therapy for definite thrombotic mechanical valve obstruction in the tricuspid or pulmonary valve position (8 in each position). All study patients except one had subtherapeutic international normalized ratios. The 8 patients with pulmonary mechanical valve thrombosis had a 100% response rate to thrombolytic therapy, and their in-hospital survival rate was also 100%. The 8 patients with tricuspid mechanical valve thrombosis had a 75% response rate to thrombolytic therapy, with an in-hospital survival rate of 87.5%. The one-year survival rate for mechanical valve thrombosis treated with thrombolytic therapy (whether pulmonary or tricuspid) was 87.5%. On the basis of our data, we recommend that thrombolytic therapy remain the firstline therapy for right-sided mechanical valve thrombosis in adults or children—including children with complex congenital heart disease and patients with mechanical pulmonary valve thrombosis. Surgery should be reserved for patients in whom this treatment fails.

AB - Data regarding thrombolytic treatment of right-sided mechanical valve thrombosis are almost nonexistent, and all current guidelines arise from very small case series. We retrospectively studied the in-hospital and long-term outcome data of a larger series of patients who had received, from September 2005 through June 2012, thrombolytic therapy for right-sided mechanical pulmonary valve or tricuspid valve thrombosis. We identified 16 patients aged 8–67 years who had undergone thrombolytic therapy for definite thrombotic mechanical valve obstruction in the tricuspid or pulmonary valve position (8 in each position). All study patients except one had subtherapeutic international normalized ratios. The 8 patients with pulmonary mechanical valve thrombosis had a 100% response rate to thrombolytic therapy, and their in-hospital survival rate was also 100%. The 8 patients with tricuspid mechanical valve thrombosis had a 75% response rate to thrombolytic therapy, with an in-hospital survival rate of 87.5%. The one-year survival rate for mechanical valve thrombosis treated with thrombolytic therapy (whether pulmonary or tricuspid) was 87.5%. On the basis of our data, we recommend that thrombolytic therapy remain the firstline therapy for right-sided mechanical valve thrombosis in adults or children—including children with complex congenital heart disease and patients with mechanical pulmonary valve thrombosis. Surgery should be reserved for patients in whom this treatment fails.

KW - Alteplase/ therapeutic use

KW - Echocardiography

KW - Fluoroscopy

KW - Heart valve prosthesis

KW - Mechanical/ dysfunction/mortality

KW - Pulmonary valve

KW - Recombinant tissue plasminogen activator/therapeutic use

KW - Streptokinase/ therapeutic use

KW - Thromboembolism/ drug therapy

KW - Thrombolytic therapy

KW - Transesophageal

KW - Treatment outcome

KW - Tricuspid valve

UR - http://www.scopus.com/inward/record.url?scp=84949215098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949215098&partnerID=8YFLogxK

U2 - 10.14503/THIJ-14-4659

DO - 10.14503/THIJ-14-4659

M3 - Article

C2 - 26664307

AN - SCOPUS:84949215098

VL - 42

SP - 543

EP - 547

JO - Texas Heart Institute Journal

JF - Texas Heart Institute Journal

SN - 0730-2347

IS - 6

ER -